First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer
Go back to First Patient Dosed in Clinical Study of TLX250-CDx in Bladder Cancer| TRANS-LUX CORPORATION (NASDAQ: TLX) | Delayed: 11.90 +0.59 (5.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $11.31 | 52 Week High | $2.18 | |||
| Open | $11.93 | 52 Week Low | $0.30 | |||
| Day High | $12.10 | P/E | N/A | |||
| Day Low | $11.83 | EPS | $-3.32 | |||
| Volume | 256,038 | |||||
